Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
暂无分享,去创建一个
J. Blay | C. Lucchesi | O. Mir | M. Toulmonde | A. Italiano | R. Boidot | O. Bouché | F. Ghiringhelli | C. Bellera | F. Le Loarer | N. Penel | N. Isambert | E. Bompas | F. Duffaud | T. Esnaud | D. Geneste | F. le Loarer
[1] M. Benelli,et al. Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response , 2017, Breast Care.
[2] R. Verardo,et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer , 2016, Oncotarget.
[3] F. Chibon,et al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. , 2016, The Lancet. Oncology.
[4] S. Loi,et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet Oncology.
[5] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[6] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[7] M. Lerman,et al. LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication. , 2012, Biochimie.
[8] J. Blay,et al. Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib , 2012, Annals of Surgical Oncology.
[9] R. Sciot,et al. Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors , 2011, Clinical Cancer Research.
[10] P. Houghton,et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. , 2011, Biochemical and biophysical research communications.
[11] V. Velculescu,et al. Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.
[12] J. Blay,et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity , 2010, Nature Medicine.
[13] J. Blay,et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs , 2009, British Journal of Cancer.
[14] A. B. Lyons,et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation , 2007, Molecular Cancer Therapeutics.
[15] K. Helin,et al. E2F target genes: unraveling the biology. , 2004, Trends in biochemical sciences.
[16] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[17] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[18] P. He,et al. LRRC3B is downregulated in non-small-cell lung cancer and inhibits cancer cell proliferation and invasion , 2015, Tumor Biology.
[19] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.
[20] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.